4D Molecular Therapeutics names new accounting chief
4D Molecular Therapeutics, Inc. announced a leadership change in its finance function.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
4D Molecular Therapeutics, Inc. announced a leadership change in its finance function. On March 25, 2026, the Board appointed Kristian Humer as the company’s Principal Accounting Officer, effective immediately. He will hold this role in addition to serving as Chief Financial Officer and Principal Financial Officer.
Humer succeeds Ashoo Gupta in the Principal Accounting Officer role; Gupta remains Vice President, Finance and Controller. The filing highlights Humer’s prior experience as CFO at Foghorn Therapeutics and Viridian Therapeutics and his earlier senior investment banking roles at Citigroup focused on healthcare.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Appointment date: March 25, 2026
Age of appointee: 51 years
2 metrics
Appointment date
March 25, 2026
Date Board appointed Principal Accounting Officer
Age of appointee
51 years
Age of Kristian Humer at time of appointment
Key Terms
Principal Accounting Officer, Principal Financial Officer, Emerging growth company, Item 5.02, +1 more
5 terms
Principal Accounting Officer financial
"appointed Kristian Humer as the Company’s Principal Accounting Officer, effective immediately"
The Principal Accounting Officer is the person responsible for making sure a company's financial records are accurate and follow the rules. They play a key role in preparing financial reports that show how well the company is doing. This helps investors, managers, and regulators trust the company's financial information.
Principal Financial Officer financial
"has served as the Company’s Chief Financial Officer and Principal Financial Officer since November 2025"
The principal financial officer is the senior executive who runs a company's financial operations: preparing and certifying financial reports, managing accounting controls, budgets and cash flow, and advising on financial strategy. Investors care about this role because its competence affects how trustworthy the company’s numbers are, how well it manages risk and capital needs, and the credibility of forecasts—like the chief navigator steering a firm's financial course.
Emerging growth company regulatory
"Emerging growth company Item 5.02 Departure of Directors or Certain Officers"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Item 5.02 regulatory
"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers"
Nasdaq Global Select Market market
"Common Stock, $0.0001 par value per share | FDMT | Nasdaq Global Select Market"
A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What leadership change did 4D Molecular Therapeutics (FDMT) disclose in this 8-K?
4D Molecular Therapeutics disclosed that its Board appointed Kristian Humer as Principal Accounting Officer effective March 25, 2026. He already serves as Chief Financial Officer and Principal Financial Officer, consolidating key finance and accounting responsibilities under a single executive leader.
Who is replacing whom as Principal Accounting Officer at 4D Molecular Therapeutics (FDMT)?
Kristian Humer is replacing Ashoo Gupta as Principal Accounting Officer at 4D Molecular Therapeutics. Gupta will continue with the company in her existing position as Vice President, Finance and Controller, maintaining continuity in the broader finance organization while shifting the designated accounting officer role.
What is Kristian Humer’s current role at 4D Molecular Therapeutics (FDMT)?
Kristian Humer serves as Chief Financial Officer and Principal Financial Officer and has now been appointed Principal Accounting Officer. This means he oversees the company’s overall financial management and is also designated as the primary officer responsible for accounting oversight and related SEC reporting functions.
What prior experience does Kristian Humer bring to 4D Molecular Therapeutics (FDMT)?
Kristian Humer previously served as Chief Financial Officer at Foghorn Therapeutics and as Chief Financial Officer and Chief Business Officer at Viridian Therapeutics. Before those roles, he spent over a decade at Citigroup Global Markets, most recently as Managing Director in the Healthcare Investment Banking Group.
When did the Board of 4D Molecular Therapeutics (FDMT) approve this officer change?
The Board of 4D Molecular Therapeutics approved the appointment of Kristian Humer as Principal Accounting Officer on March 25, 2026. The change was effective immediately as of that date, and the company later recorded the event in its current report signed by President and Chief Executive Officer David Kirn.
Does Ashoo Gupta remain with 4D Molecular Therapeutics (FDMT) after this change?
Yes. Although Ashoo Gupta is no longer designated as Principal Accounting Officer, she continues as Vice President, Finance and Controller. This preserves leadership continuity in the finance team while reassigning the formal Principal Accounting Officer title to Chief Financial Officer and Principal Financial Officer Kristian Humer.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates